9ERY

Co-crystal strucutre of PD-L1 with low molecular weight inhibitor

Summary for 9ERY

Entry DOI	10.2210/pdb9ery/pdb
Descriptor	Programmed cell death 1 ligand 1, 5-[[5-[[2-[bis(fluoranyl)methyl]-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]methoxy]-2-[(2-hydroxyethylamino)methyl]phenoxy]methyl]pyridine-3-carbonitrile, SULFATE ION, ... (4 entities in total)
Functional Keywords	pd-l1, inhibitor, immunotheraphy, immune system
Biological source	Homo sapiens (human)
Total number of polymer chains	2
Total formula weight	30577.82
Authors	Plewka, J.,Magiera-Mularz, K.,Zhang, W. (deposition date: 2024-03-25, release date: 2024-07-24, Last modification date: 2024-07-31)
Primary citation	Zhang, F.,Zhang, H.,Zhou, S.,Plewka, J.,Wang, M.,Sun, S.,Wu, C.,Yu, Q.,Zhu, M.,Awadasseid, A.,Wu, Y.,Magiera-Mularz, K.,Zhang, W. Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors. Eur.J.Med.Chem., 276:116683-116683, 2024 Cited by PubMed: 39032403 DOI: 10.1016/j.ejmech.2024.116683 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.7 Å)

Structure validation